Clinical Trial: A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Scler

Brief Summary: To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.

Detailed Summary: This is a prospective, observational, single-blinded, longitudinal, 24-month MRI study of the evolution of iron deposits, as evidenced by SWI-filtered phase imaging, in RRMS patients treated with GA and in healthy controls.
Sponsor: University at Buffalo

Current Primary Outcome: To explore whether treatment with GA may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls. [ Time Frame: 24 months ]

MRI collected from RRMS patients who have taken Copaxone for 24 months


Original Primary Outcome: Same as current

Current Secondary Outcome: To investigate whether treatment with GA may decrease accumulation of iron in lesions, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months. [ Time Frame: 24 months ]

Evaluate if Copaxone will decrease iron in lesions.


Original Secondary Outcome: Same as current

Information By: University at Buffalo

Dates:
Date Received: September 26, 2012
Date Started: June 2012
Date Completion:
Last Updated: March 21, 2013
Last Verified: March 2013